摘要
目的通过Meta分析对比采用雷替曲塞与氟尿嘧啶行TACE治疗中晚期原发性肝癌的疗效及安全性。方法结合计算机及人工检索PubMed、Cochrane Library、Web of Science、中国生物医学文献数据库、万方数据库及中国知网收录的有关对比分析雷替曲塞与氟尿嘧啶TACE治疗中晚期原发性肝癌的文献,并从中提取相关资料。通过Meta分析方法对2种TACE的客观有效率(ORR)、疾病控制率(DCR)、患者总生存率(OS)及术后不良反应进行评价。结果最终8篇文献、共635例患者纳入分析。雷替曲塞TACE的ORR[相对危险度(RR)=1.25,95%CI(1.06,1.47),P=0.008]及DCR[RR=1.17,95%CI(1.08,1.26),P<0.001]均高于氟尿嘧啶TACE,期间患者OS[RR=1.15,95%CI(0.95,1.39),P=0.141]及术后不良反应[恶心、呕吐:RR=0.90,95%CI(0.73,1.11),P=0.339;发热:RR=0.90,95%CI(0.77,1.06),P=0.219;肝区疼痛:RR=0.90,95%CI(0.80,1.01),P=0.219;外周血白细胞减少:RR=0.89,95%CI(0.65,1.21),P=0.462;转氨酶升高:RR=0.96,95%CI(0.80,1.16),P=0.663]差异均无统计学意义。结论 TACE治疗中晚期原发性肝癌时,采用雷替曲塞较氟尿嘧啶疗效更优,安全性则相似。
Objective To compare the efficacy and safety of raltitrexed and fluorouracil in TACE for treatment of middle and advanced primary liver cancer.Methods PubMed,Cochrane Library,Web of Science,China Biology Medicine disc,Wanfang database and China National Knowledge Internet were searched manually and with computer for literature involved comparative analysis of the efficacy and safety of raltitrexed and fluorouracil in TACE for treatment of middle and advanced primary liver cancer,and then the relevant data were extracted.The objective response rate(ORR),disease control rate(DCR),overall survival(OS)and postoperative adverse reactions were evaluated for Meta-analysis.Results A total of 8 papers(covering 635 patients)were included.ORR(relative risk[RR]=1.25,95%CI[1.06,1.47],P=0.008)and DCR(RR=1.17,95%CI[1.08,1.26],P<0.001)of raltitrexed in TACE was higher than those of fluorouracil.There was no statistical difference of OS(RR=1.15,95%CI[0.95,1.39],P=0.141)nor incidence of postoperative adverse reaction(nausea and/or vomiting:RR=0.90,95%CI[0.73,1.11],P=0.339;fever:RR=0.90,95%CI[0.77,1.06],P=0.219;hepatalgia:RR=0.90,95%CI[0.80,1.01],P=0.219;peripheral leucopenia decreasing:RR=0.89,95%CI[0.65,1.21],P=0.462;transaminase elevation:RR=0.96,95%CI[0.80,1.16],P=0.663)between the two drugs used in TACE.Conclusion Raltitrexed is more effective than fluorouracil in TACE for treatment of middle and advanced primary liver cancer,and the safeties of both drugs are similar.
作者
周凡
赵倩
徐浩
祖茂衡
许伟
ZHOU Fan;ZHAO Qian;XU Hao;ZU Maoheng;XU Wei(Department of Interventional Radiology,the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006,China;Department of Endocrinology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006,China)
出处
《中国介入影像与治疗学》
CSCD
北大核心
2018年第11期655-660,共6页
Chinese Journal of Interventional Imaging and Therapy
关键词
雷替曲塞
氟尿嘧啶
化学栓塞
治疗性
肝肿瘤
综合分析
Raltitrexed
Fluorouracil
Chemoembolization,therapeutic
Liver neoplasms
Meta-analysis
